Enduring Material

Psoriatic disease in underserved communities
View Activity Info
Enter Basic User Info
View Content
Take Post Test
Create Account
Done
View Activity Info
Continue to Enduring Material
 
 
National Psoriasis Foundation

1800 Diagonal Road, Suite 360
Alexandria, VA 22314
General Information
Tuesday, July 12, 2022 - Friday, July 12, 2024
15 minutes
National Psoriasis Foundation
Virtual Conference Room
Psound Bytes CME Podcast
National Psoriasis Foundation
Objectives
  • Understand the impact of psoriatic disease on underserved populations
Presentations and Speakers
Psoriatic disease in underserved communities
  • Tina Bhutani, MD
Available Credits/Points
  • The National Psoriasis Foundation designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • The National Psoriasis Foundation designates this enduring material for a maximum of 0.25 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Hear Dr. Tina Bhutani, M.D., MAS, assistant professor at the University of California San Francisco, discuss the impacts psoriatic disease has on underserved minorities. This podcast was supported by the Centers for Disease Control and Prevention of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $326,934 with 3 percentage funded by CDC/HHS and $100,000 amount and 12 percentage funded by non- government source(s). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CDC/HHS, or the U.S. Government. This program is supported by educational grants from Amgen, Novartis, Pfizer, and UCB.
Disclosure Statements
NPF Staff/Planning Committee, has disclosed no relevant financial relationships with commercial interests.
Speakers:
Tina Bhutani, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • Sanofi - Consulting - Relationship Ended
  • Leo - Consulting - Relationship Ended
  • UCB - Consulting - Relationship Ended
  • Arcutis - Consulting - Relationship Ended
  • BI - Consulting - Relationship Ended
  • Abbvie - Consulting - Relationship Ended
  • BMS - Consulting - Relationship Ended
  • Janssen - Consulting - Relationship Ended
  • Novartis - Consulting - Relationship Ended
  • ASLAN - DMC Member - Relationship Has Not Ended
  • Abbvie - Contracted Research - Relationship Has Not Ended
  • Castle - Contracted Research - Relationship Has Not Ended
  • Dermavant - Contracted Research - Relationship Has Not Ended
  • Novartis - Contracted Research - Relationship Has Not Ended
  • Regeneron - Contracted Research - Relationship Has Not Ended
  • Galderma - Contracted Research - Relationship Has Not Ended
  • Pfizer - Contracted Research - Relationship Has Not Ended
Any financial relationship that was found to be relevant has been mitigated.

Any relevant financial relationships have been mitigated.
Support for this activity is gratefully acknowledged from Amgen. Support for this activity is gratefully acknowledged from Novartis. Support for this activity is gratefully acknowledged from Pfizer. Support for this activity is gratefully acknowledged from UCB.
Accreditation Statement
  • The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Test Information
0 %
100 %
7/12/2022
Continue to Enduring Material